Aflibercept 16-Week Dosing Regimen for Diabetic Retinopathy Under Review
The sBLA is supported by data from the phase 3 PANORAMA trial and the NIH-sponsored Protocol W trial.
Ophthalmic Disorders
Lutein/Zeaxanthin in AREDS2 May Slow Progression to Late AMD
No increased risk for lung cancer, reduced risk for progression to late AMD seen with lutein/zeaxanthin as replacement for beta-carotene
Update on Availability of Byooviz, a Biosimilar to Lucentis
Byooviz (ranibizumab-nuna) is indicated for the treatment of neovascular (wet) age-related macular degeneration, macular edema following retinal vein occlusion, and myopic choroidal neovascularization.
USPSTF: Evidence Lacking for Glaucoma Screening in Adults
And in second recommendation statement, evidence insufficient for screening asymptomatic older adults for impaired visual acuity
Nyxol Ophthalmic Solution Looks Promising for Night Vision Disturbances
The trial included 145 patients who experienced vision impairment under dim light conditions.
Verkazia Now Available for Vernal Keratoconjunctivitis
Verkazia is an oil-in-water cationic emulsion that works by inhibiting T-cell activation and reducing the level of immune cells and mediators.
Continued Monitoring Needed for Anti-VEGF Therapy in Macular Edema
Substantial improvement observed through month 12, which persisted through month 60, but lessened with fewer treatments
Trials Evaluating Novel Eye Drop Candidate for Presbyopia Meet Endpoints
The phase 3 NEAR-1 and NEAR-2 trials included 613 patients aged 45 to 64 years with presbyopia.
Erectile Dysfunction Meds Tied to Higher Risk for Vision Issues
Regular users may be at risk for serous retinal detachment, retinal vascular occlusion, and ischemic optic neuropathy
Trial Investigating New Vuity Dosing Option for Presbyopia Meets Endpoint
The phase 3 VIRGO study evaluated the efficacy and safety of Vuity in adults aged 40 to 55 years of age with presbyopia.
